Media coverage
2Media coverage
Title FDA Approves Stiolto® Respimat® Supplemental New Drug Application (sNDA) to Add Data on COPD Exacerbation Reduction; Stiolto Respimat is the first in its class to have exacerbation data in the product labeling Media name/outlet PR Newswire Country United States Date 10/11/18 Persons Antonio R Anzueto Title FDA Approves Stiolto® Respimat® Supplemental New Drug Application (sNDA) to Add Data on COPD Exacerbation Reduction; Stiolto Respimat is the first in its class to have exacerbation data in the product labeling Media name/outlet PR Newswire Country United States Date 10/11/18 Persons Antonio R Anzueto